 - Early Data from Study of GPS in Combination with Keytruda in Patients with Advanced WT1 Ovarian Cancer Shows Disease Control Rate of 87.5 at a Median Follow-up of 9.4 Weeks and 100 Progression Free Survival at 6 Weeks - 